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Summary The effect of the maturation-inducing polar solvent, hexamethylene bisacetamide (HMBA), on the
radiosensitivity of two human tumour cell lines (clone A, a colon carcinoma; and EJ, a bladder carcinoma)
was investigated. Exposure of clone A or EJ cells to HMBA resulted in a concentration-dependent increase in
doubling time, a decreased plating efficiency and changes in cell morphology, which are consistent with the
formation of a better-differentiated phenotype. Growth of clone A cells in 2 or 3 mM HMBA, followed by
irradiation and plating into HMBA-free medium, resulted in a significant enhancement in radiosensitivity, as
determined by colony-forming ability. A similar increase in radiosensitivity was detected for EJ cells; however,
for these cells a concentration of 7 mM HMBA was required. The increased radiosensitivity caused by HMBA
was observed primarily in the low-dose, shoulder region of the y-ray cell survival curves for both cell lines,
which is reflected by an increase in the a component of the survival curve with essentially no effect on P. These
data indicate that HMBA can radiosensitise human tumour cells at concentrations and for exposure periods
that can be achieved in the clinic.
The polar-solvent class of maturational agents can induce the
terminal differentiation of a number of leukaemic cell lines in
vitro (reviewed by Spremulli & Dexter, 1984). The treatment
of many cell lines derived from solid tumours with the polar
solvents, however, does not result in terminal differentiation,
but merely the formation of a less malignant or better differ-
entiated phenotype. This form of differentiation is charac-
terised by an increase in cell culture doubling time, a decrease
in clonigenicity, changes in cell morphology, a decrease in
tumorigenicity when injected into nude mice and the produc-
tion of specialised cell products associated with normal cells
(Spremulli & Dexter, 1984). While anti-neoplastic benefits,
such as a decrease in tumour aggressiveness, may be obtained
from these types of cellular changes, upon withdrawal of the
polar compounds, cells revert to their original malignant
state. The reversible nature of these phenotypic changes sug-
gests that only limited, if any, advantages might be gained
from the use of differentiation-inducing polar solvents as
single agents in the treatment of solid tumours.
However, exposure of sevcral tumour cell lines to the polar
solvents N-methylformamide (NMF) and N, N-dimethylfor-
mamide (DMF) was found not only to result in the forma-
tion of a better differentiated phenotype but also to enhance
the radiosensitivity of these cells (Leith et al., 1982, 1985). In
addition, NMF exposure was shown to increase the radiosen-
sitivities of eight of 10 human primary tumour cell cultures
(Arundel et al., 1987). In vivo, Dexter et al. (1984) found that
the administration of NMF to nude mice enhanced the
growth-inhibitory action of ionising radiation on a human
colon tumour xenograft. In a subsequent study by Iwakawa
et al. (1987), treatment of C3H mice bearing a murine fibro-
sarcoma with NMF enhanced the radiosensitivity of the
primary tumour and its pulmonary metastases, yet had no
effect on the radioresponse of normal tissue. Such observa-
tions in experimental tumour systems suggested that differ-
entiation-inducing polar solvents administered in combina-
tion with radiotherapy may provide clinical benefits in cancer
treatment.
With respect to NMF, its application as a clinically
effective radiosensitiser appears unlikely. The in vitro concen-
tration of NMF required to induce the formation of a better
differentiated phenotype and the radiosensitisation of tumour
cells is approximately 170 mM (Leith et al., 1985). Yet the
achievable NMF plasma concentration in humans is 1.7 mM
(Orr et al., 1983). In mice, the maximum plasma concentra-
tion of NMF is only 7 mM (Brindley et al., 1982), which
suggests that the radiosensitisation detected in the experi-
mental in vivo systems is not the result of the parent drug,
but of some NMF metabolite(s).
Although NMF has received the most attention as the
prototype polar-differentiating agent, it is actually HMBA
that is the most potent inducer of erythroid differentiation of
all the polar compounds investigated (Reuben et al., 1976).
Exposure of leukaemic cells in vitro to concentrations of
1-5 mM HMBA has been reported to result in terminal
differentiation, as compared with 150-200 mM NMF (Chun
et al., 1986). The greater potency of HMBA suggested that it
may be of possible clinical use as a differentiating agent.
Indeed, recent pharmacokinetic studies have revealed that by
using constant i.v. infusion, steady-state plasma concentra-
tions of 1-2 mM HMBA can be maintained for 5- 10 days
with acceptable toxicity (Egorin et al., 1987; Young et al.,
1988; Conley et al., 1989). These levels are well within the
range required to induce in vitro the terminal differentiation
of leukaemic cells, and for solid tumour cells, the formation
of a better differentiated phenotype (Hughes et al., 1982). In
addition, because HMBA is excreted via the urine (Egorin et
al., 1987), considerably higher concentrations can be main-
tained specifically in the urinary bladder. The elimination
characteristics of HMBA thus suggest that it may be espe-
cially suited for treatment of some bladder cancers (Rifkind
et al., 1988).
In light of this encouraging human pharmacokinetic data,
we have investigated the effects of HMBA on the radiosen-
sitivity of two human tumour cell lines derived from colon
(clone A) and bladder (EJ) carcinomas. The data presented
indicate that at clinically achievable concentrations, HMBA
enhances the radiosensitivity of both lines.
Materials and methods
Cell culture
Clone A cells, originally isolated from a human colon adeno-
carcinoma, were grown in RPMI 1640 medium supplemented
with 10% fetal bovine serum, buffers and antibiotics, as
described by Leith et al. (1982). EJ cells, isolated from
a spontaneously occurring human bladder carcinoma, were
obtained from the American Type Culture Collection (Rock-
ville, MD, USA) and grown in McCoy's 5A medium contain-
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ing 10% fetal bovine serum, buffers and antibiotics. Cultures
were routinely maintained in 75 cm2 plastic tissue culture
flasks and were incubated at 37°C in a humidified atmo-
sphere of 95% air/5% CO2. Clone A and EJ cells were
seeded into 25 or 75 cm2 tissue culture flasks at least 24 h
before being used in an experiment.
Cell treatment
HMBA (Sigma Chemical Company, St Louis, MO, USA) was
dissolved in solution A (8 g NaCl, 0.4 g KCl, 1 g d-glucose,
0.35 g NaHCO3 per litre of water) to a stock concentration of
200 mM and stored in the dark at 4°C. The appropriate
volume of stock HMBA solution was added to cultures for a
specified time. Irradiations were performed using a "'CS
source, with a dose rate of 4.5 Gy min-'.
Cell survival assay and analysis
Cells were irradiated in monolayer at room temperature,
trypsinized with 0.05% trypsin/l mM EDTA solution and
replated in specified numbers into 60 mm dishes for deter-
mination of colony-forming ability. After 9-12 days of
incubation, colonies were stained with 0.5% crystal violet
in absolute methanol, and the surviving fractions were deter-
mined. Radiation survival curves were generated by combin-
ing data from three to four independent experiments and
fitting the average survival levels by least-squares regression
using the linear-quadratic model, as described by Fertil and
Malaise (1981). The linear-quadratic model was shown to be
appropriate for estimating low dose effects (Fertil & Malaise,
1981) and is based on the equation: -lnS = ocD +PD2, in
which S is the surviving fraction, D is the dose of radiation
and a and P represent inactivation constants relating to
one-hit and two-hit cell killing, respectively (Chadwick &
Leenhouts, 1973).
Cell cycle analysis
Cells were fixed in 70% aqueous ethanol and stained with
ethidium bromide (12.5 gg ml-')/mithramycin (25 pg ml-').
Samples were processed using an Ortho Instruments ICP21
flow cytometer (Phywe, Gottingen, FR Germany). Cell-cycle
phase distributions were estimated by computer analysis of
the DNA histograms, according to Johnston et al. (1978).
Results
In our initial characterisation of the effects of HMBA on
clone A and EJ cells, growth curves were constructed for
each cell line exposed to the continued presence of various
HMBA concentrations (Figure 1). The growth rates of clone
A and EJ cell cultures were decreased in an HMBA con-
centration-dependent manner. Clone A cells, however, were
more sensitive than EJ to the growth-inhibitory actions of
HMBA. For both cell lines, the increase in culture doubling
time was accompanied by a decrease in plating efficiency
(Table I), a decrease in cell culture saturation density (data
not shown) and changes in cell morphology, which are char-
acteristic of the formation of a better differentiated pheno-
type (Spremulli & Dexter, 1984).
Previous studies using clone A cells have shown that the
conversion to a better differentiated phenotype as a result of
exposure to NMF, DMF or sodium butyrate is also accom-
panied by an increase in the cytotoxicity induced by ionising
radiation (Leith et al., 1982, 1985; Arundel et al., 1985). To
determine whether this also occurs for HMBA, we evaluated
the effect of this maturational agent on the radiosensitivity of
clone A cells (Figure 2, Table I). For each HMBA/y-ray
survival curve, the results were normalised to account for the
cell killing induced by HMBA alone; the surviving fractions
after 2 and 3 mM HMBA exposures were 0.74 and 0.70,
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Figure 1 Growth responses ofclone A (a) and EJ cells (b) to the
continual presence of various concentrations of HMBA. Values
represent the mean of two experimental points.
Table I Effects of HMBA on the y-ray survival curve parameters of
clone A and EJ cellsa
HMBA(mM) a(Gy-') p(Gy-2) S2b PEC
Clone A 0 0.023 0.067 0.73 0.54 0.04
2 0.152 0.069 0.56 0.40± 0.02
3 0.196 0.063 0.53 0.38±0.02
EJ 0 0.068 0.051 0.71 0.60 0.02
6 0.053 0.052 0.76 0.17 ± 0.03
7 0.334 G.042 0.43 0.24 ± 0.06
8 0.296 0.040 0.47 0.14 ± 0.03
'Clone A cells were grown in the presenceofHMBA for96 h; EJcells
were exposed to 7 and 8 mM HMBA for 72 h and 6 mM HMBA for
120 h. Parameters (a, P and S2) were calculated from y-ray survival
curves generated using the linear quadratic model and the combined
results from 3-4independentexperiments asdescribed inMaterials and
methods. The actual v-ray survival curves for Clone A and EJ cells
treated with 3 and 7 mM HMBA, respectively, are shown in Figure 2.
bSurviving fraction at 2 Gy. cPlating efficiency for cells treated with
HMBA only. Data represent the mean ± s.e. obtained from the 3-4
independent experiments.
shown in Table I. As shown in Figure 2, growth of this cell
line in the presence of 3 mM HMBA for 96 h before 7-irrad- iation significantly enhanced clone A cell radiosensitivity. Although 2 mM did result in an enhancement in radiosen- sitivity (Table I), exposure to 3 mM HMBA provided the maximum increase in y-ray induced cell killing. No further enhancement in clone A radioresponse was achieved by in-
creasing HMBA dose or exposure time.
The HMBA-induced radiosensitisation of clone A cells
occurs primarily in the low-dose, shoulder region of the y-ray cell survival curve. Data from experiments using 2 and 3 mM HMBA exposures for 96 h were fitted to the linear-quadratic equation, and the a and P inactivation constants were cal- culated (Table I). HMBA exposure resulted in an increase in the a values with little, if any, change in P. According to the x-P model for radiation-induced cell killing (Chadwick & Leenhouts, 1973), this would suggest an increase in one-hit killing by y-rays in HMBA-treated clone A cells, with no change in the level of killing as a result of the two-hit
component. Recent investigations into the relationship be-
tween in vitro radiation survival curve parameters and the radioresponse of tumours in vivo have shown that survival at 2 Gy (calculated from survival curves constructed using the linear-quadratic model) correlates well with relative in vivo
tumour radiosensitivity (Fertil & Malaise, 1981; Deacon et al., 1984; Malaise et al., 1987). Thus, in Table I we have listed the survival at 2Gy (S2) calculated for the various survival curves. For both 2 and 3 mM HMBA, a significant decrease in S2 is detected. No further decrease is detected at HMBA doses greater than 3 mM.











Figure 2 Radiation survival responses of clone A and EJ cells.
Clone A cells were grown for 96 h with (U) or without (0)
3 mM HMBA, and EJ cells were grown for 72 h with (0) or
without (0) 7 mM HMBA in the growth medium. Cells were
trypsinised immediately after irradiation and plated for colony-
forming ability in HMBA-free medium. Values represent the
mean ± s.e. of 3-4 independent experiments. Data have been
normalised to account for the decrease in plating efficiency
induced by HMBA treatment only.
In a manner similar to that of clone A, pretreatment of EJ
cells with HMBA also resulted in a significant enhancement
in cellular radiosensitivity. For EJ cells, however, a greater
HMBA concentration was required, 7 mM for 72 h (Figure
2). No sensitisation was detected at 6 mM for exposure times
up to 5 days, and no further radiosensitisation was detected
using HMBA concentrations greater than 7 mM (Table I). As
shown in Table I, the enhancement in y-ray induced cell
killing in EJ cells exposed to 7 or 8 mM HMBA is primarily
expressed as an increase in the a inactivation constant and,
in contrast to clone A, a slight decrease in P. S2 is also
significantly reduced in EJ cells exposed to 7 or 8 mM.
Again, these data indicate that HMBA increases the one-hit
cell killing by y-rays, primarily affecting the low-dose,
shoulder region of the y-ray cell survival curve. Complicating
the interpretation of these combination experiments, how-
ever, is the level of EJ cell killing induced by HMBA alone
(Table I). Concentrations of 6, 7 and 8 mM HMBA each
substantially reduces the plating efficiency of EJ cells, yet
an enhancement in radiosensitivity occurs only for 7 and
8 mM. Based on these data, there does not appear to be a
cause - effect relationship between the cytotoxic and detected
radiosensitising actions of HMBA.
The sensitivity of mammalian cells to ionising radiation
can vary according to their position in the cell cycle
(Denekamp, 1986). Thus, to determine the possible role of a
cell-cycle effect on HMBA-induced radiosensitisation, clone
A and EJ cells were incubated with HMBA under the condi-
tions that gave the maximum radioresponse (Figure 2) and
their cell-cycle phase distributions were analysed (Table II).
HMBA had no significant effect on the cell-cycle phase distri-
butions of clone A cells. For EJ cells, however, there was a
significant increase in the GI phase population.
Discussion
Differentiation therapy (i.e. the administration ofcompounds
capable of inducing tumour cell differentiation) has been
suggested as an alternative to the use of more traditional
cytotoxic agents in cancer treatment (Bloch, 1984). The
putative advantage of this form of anti-neoplastic therapy is
that differentiating agents would be relatively specific for
tumours, and consequently would result in only minimal
normal tissue toxicity. Although differentiation therapy may
show promise for the treatment of certain haematological
malignancies and dysplasias, laboratory investigations sug-
gest that little benefit would be gained from the use of these
agent as a single modality in the treatment of most solid
tumours. As previously stated, this apparent lack of clinical
potential is due to the non-terminal, reversible nature of the
differentiation induced in these cells. When administered in
combination with cytotoxic agents, however, experimental
studies do suggest that differentiating compounds may indeed
contribute to the effectiveness of cancer treatment. The polar
maturational compounds NMF, DMF and sodium butyrate,
which induce the formation of a better differentiated
phenotype, have all been shown to enhance the sensitivity of
a tumour cell line or lines to ionising radiation and/or to
several cytotoxic anti-neoplastic drugs (Leith et al., 1982,
1985; Arundel et al., 1985). Because of either limited potency
or unfavourable pharmacokinetics, however, these com-
pounds are not suitable for clinical use. In contrast, human
pharmacokinetics studies have shown that the plasma levels
of HMBA, which can be maintained for up to 10 days, are
within the range required to induce the differentiation of
tumour cells in vitro. Yet, to our knowledge, the combination
of HMBA with cytotoxic agents has received little, if any,
research attention. The data presented here demonstrate that
prior exposure to HMBA can significantly enhance the radio-
sensitivity of two human tumour cell lines. This sensitisation
is most pronounced using clinically relevant, low doses of
radiation (Table I).
The degree of radiosensitisation of clone A cells induced
by HMBA is similar to that induced by NMF (Leith et al.,
1985). In addition, both compounds affect the initial slope
of the y-ray cell survival curve. There is a significant
difference, however, between the sensitisation induced by
these two polar compounds regarding the concentrations
required: 2-3 mM of HMBA versus 170 mM of NMF. A
Table II Effect of HMBA on the cell-cycle phase distribution of clone A and EJ cell
cultures
Treatment G, cells (%) S cells (%) G2M cells (%)
Clone A control 49.4 33.7 16.9
HMBA (3 mM) 43.0 40.1 16.6
EJ control 39.3 36.4 24.0
HMBA (7 mM) 83.6 8.3 8.6
aCloneA cell cultures were treatedwith 3 mM HMBA for96 h and EJ cells were treated
with 7 mM HMBA for 72 h. Controlcultureswereseeded atthe sametime asthosetreated
with HMBA but at a lowerdensity to ensure anexponentially growing culture at the time
of fixation. Phase distributions were estimated from computer analysis of DNA
histograms obtained by flow cytometry.566 C.A. BILL et al.
difference in concentration of similar magnitude exists
between NMF and HMBA with respect to the terminal
differentiation of leukaemic cells and the non-terminal differ-
entiation of solid tumour cells (Spremulli & Dexter, 1984;
Reuben et al., 1976; Hughes et al., 1982). Our data, illus-
trating the HMBA-mediated radiosensitisation of clone A
cells, however, are in contrast to the findings of Leith et al.
(1986). These investigators state that even in the presence of
morphological changes, HMBA had no effect on the radio-
response of clone A cells. It is possible that the cells have
changed or that different serum lots may be involved. At this
time, however, we are unable to account for these contrasting
results.
In order to induce the radiosensitisation of the human
bladder tumour cell line EJ, it was necessary to use 7 mM
HMBA. Although this concentration is considerably greater
than that required for clone A cells, it is still within the
HMBA level clinically achievable within the urinary bladder.
The necessity to increase HMBA concentrations also resulted
in a significant amount of HMBA-induced cell killing. This
raises the possibility that the observed increase in radio-
sensitivity may reflect an additive effect of the individual
cytotoxicities for HMBA and y-rays. There does not, how-
ever, appear to be an obvious dose response for the decrease
in plating efficiency over the HMBA concentration used:
6 mM reduced plating efficiency essentially to the same level
as 7 and 8 mM. Yet radiosensitisation is detected only at
concentrations of 7 and 8 mM. This suggests that the
detected increase in y-ray induced cell killing is not merely
the result of an additive effect of the individual cytotoxicities
of y-rays and HMBA, but a modification in EJ response to
radiation. It should be noted that for EJ as well as for clone
A cells treated with HMBA, it is not possible to determine
whether the reduction in plating efficiency is due to the
cytotoxic actions of HMBA or is the result of terminal
differentiation.
The mechanism(s) responsible for HMBA-induced radio-
sensitisation remain to be elucidated. The maximum increase
in radiosensitivity does not occur until at least 72 h of
HMBA exposure, suggesting that the mere presence of
HMBA is not sufficient for radiosensitisation and that some
type of cellular metabolic change is required. Exposure of EJ
cells to 6 mM HMBA resulted in the morphological changes
associated with a better differentiated phenotype and yet no
enhancement in y-ray induced cell killing was detected. A
similar phenomenon was found for the NMF treatment of a
murine hepatocarcinoma cell line (i.e. NMF induced the
formation of a better differentiated phenotype with no effect
on the radiosensitivity of the cells (Arundel et al., 1988)).
These observations lend support to the idea that, although
the formation of a better differentiated phenotype may be
necessary for radiosensitisation, it is not sufficient; other
changes are required. The accumulation of EJ cells in the G1
phase of the cell cycle may account for at least some of the
radiosensitisation of this cell line. The evaluation of the
possible contribution of this mechanism awaits future studies
of the cell-cycle age response of EJ cells to y-rays. The cell
cycle, however, can be eliminated from playing a role in the
radiosensitisation of clone A cells. As was found for NMF
(Leith et al., 1985; and our own unpublished data), HMBA
has no effect on the cell-cycle distribution of clone A cells
(Table II). It has previously been shown that NMF enhances
the initial level of radiation-induced DNA double-strand
breaks in clone A cells, which can then account for an
increase in radiation-induced cell killing (Tofilon et al., 1989).
HMBA may act through a simlar process. This, however,
remains speculative and will be the subject of future investi-
gations. Regardless of the mechanisms involved, these data
presented do indicate that HMBA, at concentrations and for
exposure times that can be achieved in the clinic, can
enhance the radiosensitivity of human tumour cell lines.
This work was supported by grant no. CA-06294, National Institutes
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